专利检索 ap:("Bristol-Myers Squibb Company") AND inv:"YIN, Xiaotian S." 第 1 页

1.

发明公开
CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME 审中-公开
标题翻译：沙格列汀结晶形式和方法及其

公开(公告)号：EP2137149A2

公开(公告)日：2009-12-30

申请号：EP08746183.6

申请日：2008-04-18

申请人： Bristol-Myers Squibb Company

发明人： GOUGOUTAS, Jack Z. , MALLEY, Mary F. , DIMARCO, John D. , YIN, Xiaotian S. , WEI, Chenkou , YU, Jurong , VU, Truc Chi , JONES, Gregory Scott , SAVAGE, Scott A.

IPC分类号： C07D209/52 , A61K31/403 , A61P3/00

CPC分类号： C07D209/52 , A61K31/403 , A61K45/06 , A61K2300/00

摘要： Physical crystal structures of a compound of the formula (I): are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

2.

发明公开
CRYTALLINE FORMS OF A PYRAZOLO `3, 4-C Ü PYRIDINE FACTOR XA INHIBITOR 审中-公开
标题翻译：因子Xa抑制剂的作为作用吡唑并[3,4-C]吡啶结晶形式

公开(公告)号：EP1819703A1

公开(公告)日：2007-08-22

申请号：EP05805620.1

申请日：2005-09-27

申请人： Bristol-Myers Squibb Company

发明人： GLEESON, Margaret M. , MCGEORGE, Gary , CHEN, Bang-Chi , ZHANG, Huiping , MALLEY, Mary F. , DIMARCO, John D. , MURPHY, Denette K. , YIN, Xiaotian S. , FABIAN, Steven R. , GUPTA, Jasmine M.

IPC分类号： C07D471/04 , A61K31/437 , A61P7/02

CPC分类号： C07D471/04

摘要： The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.